Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463528 | 1.00 | S1PR1 (0.47) | S1PR1S1PR3KCNT1TLR9TLR8 | |
| SCHEMBL22637953 | 1.00 | S1PR1 (0.47) | S1PR1S1PR3KCNT1TLR9TLR8 | |
| SCHEMBL24660720 | 0.84 | S1PR1 (0.50) | S1PR1S1PR3KCNT1TLR9TLR8 | |
| SCHEMBL24660577 | 0.84 | S1PR1 (0.50) | S1PR1S1PR3KCNT1TLR9TLR8 | |
| SCHEMBL24660541 | 0.84 | S1PR1 (0.50) | S1PR1S1PR3KCNT1TLR9TLR8 | |
| Hydrochloric Acid SCHEMBL22637823 | 0.83 | S1PR1 (0.49) | S1PR1S1PR3KCNT1TLR9TLR8 | |
| Hydrochloric Acid SCHEMBL29478782 | 0.83 | S1PR1 (0.49) | S1PR1S1PR3KCNT1TLR9TLR8 | |
| SCHEMBL22637730 | 0.82 | KCNT1 (0.51) | S1PR1KCNT1 | |
| SCHEMBL22637731 | 0.82 | KCNT1 (0.51) | S1PR1KCNT1 | |
| SCHEMBL29463512 | 0.82 | KCNT1 (0.51) | S1PR1KCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | S1PR1 3183/4885S1PR3 3094/4885KCNT1 1/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | S1PR1 3183/4885S1PR3 3094/4885KCNT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.